Skip to main content
SpringerLink
Log in

Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain

  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Summary

Decreased reduced glutathione (GSH) levels are an early marker of nigral cell death in Parkinson's disease. Depletion of rat brain GSH by intracerebroventricular administration of buthionine sulphoximine (BSO) potentiates the toxicity of 6-hydroxydopamine (6-OHDA) to the nigrostriatal pathway. We have investigated whether thioctic acid can replenish brain GSH levels following BSO-induced depletion and/or prevent 6-OHDA induced toxicity.

Administration of BSO (2 × 1.6 mg ICV) to rats depleted striatal GSH levels by upto 75%. BSO treatment potentiated 6-OHDA (75 μg ICV) toxicity as judged by striatal dopamine content and the number of tyrosine hydroxylase immunoreactive cells in substantia nigra. Repeated treatment with thioctic acid (50 or 100mg/kg i.p.) over 48h had no effect on the 6-OHDA induced loss of dopamine in striatum or nigral tyrosine hydroxylase positive cells in substantia nigra. Also thioctic acid treatment did not reverse the BSO induced depletion of GSH or prevent the potentiation of 6-OHDA neurotoxicity produced by BSO.

Thioctic acid (50mg or 100mg/kg i.p.) alone or in combination with BSO did not alter striatal dopamine levels but increased dopamine turnover. Striatal 5-HT content was not altered by thioctic acid but 5-HIAA levels were increased.

Under conditions of inhibition of GSH synthesis, thioctic acid does not replenish brain GSH levels or protect against 6-OHDA toxicity. At least in this model of Parkinson's disease, thioctic acid does not appear to have a neuroprotective effect.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Anderson ME, Meister A (1989) Marked increase in cysteine levels in many regions of the brain after administration of 2-oxo-4-thiazolidine-carboxylate. FASEB J 3: 1632–1636

    Google Scholar 

  • Aw TY, Wierzbicka G, Jones DP (1991) Oral glutathione increases tissue glutathione concentration in vivo. Chem-Biol Interact 80: 89–97

    Google Scholar 

  • Busse E, Zimmer G, Schopohl B, Kornhuber B (1992) Influence of α-lipoic acid on intracellular glutathione in vitro and in vivo. Arzneimittelforschung 42: 829–831

    Google Scholar 

  • Carman LS, Gage FH, Shutts CW (1991) Partial lesion of the substantia nigra: relation between extent of lesion and rotational behaviour. Brain Res 553: 275–283

    Google Scholar 

  • Cohen G, Heikkila RE (1974) The generation of hydrogen peroxide, superoxide radical and hydroxyl radical by 6-hydroxydopamine, dialuric acid and related cytotoxic agents. J Biol Chem 249: 2447–2452

    Google Scholar 

  • Cohen G, Spina MB (1989) Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 26: 689–690

    Google Scholar 

  • Dexter DT, Wells FR, Agid F, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alterations in other metal ions in brain in Parkinson's disease. J Neurochem 52: 1830–1836

    Google Scholar 

  • Dexter DT, Sian J, Rose S, Hindmarsh JG, Mann VM, Cooper JM, Wells FR, Daniel SE, Lees AJ, Schapira AHV, Jenner P, Marsden CD (1994) Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 35: 38–44

    Google Scholar 

  • Ehrenthal W, Preilwitz W (1986) Biochemie und Pharmakologie der Liponsäure. In: Neundörfer B, Sailer D (Hrsg) Interdisziplinäre Bestandsaufnahme der Polyneuropathien. Perimed, Erlangen, S154

    Google Scholar 

  • Götz ME, Dirr A, Burger R, Janetzky B, Weinmüller M, Chan W, Chen S, Reischmann H, Rausch W-D, Riederer P (1994) Effect of lipoic acid on redox state of coenzyme Q in mice treated with 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine and diethyldithiocarbamate. Eur J Pharmacol 266: 291–300

    Google Scholar 

  • Greenamyre JT, Garcia-Osuna M, Greene JG (1994) The endogenous cofactors, thioctic acid and dihydrolipoic acid are neuroprotective against NMDA and malonic acid lesions of striatum. Neurosci Lett 171: 17–20

    Google Scholar 

  • Griffith OW (1982) Mechanism of action, metabolism and toxicity of buthionine sulfoximine and its higher homologues, potent inhibitors of glutathione synthesis. J Biol Chem 257: 13704–13712

    Google Scholar 

  • Heikkila RE, Cohen G (1973) 6-Hydroxydopamine: evidence for superoxide radicals as an oxidative intermediate. Science 181: 456–457

    Google Scholar 

  • Jain A, Mårtensson J, Stole E, Auld PA, Méister A (1991) Glutathione deficiency leads to mitochondrial damage in brain. Proc Natl Acad Sci USA 88: 1913–1917

    Google Scholar 

  • Jenner P, Schapira AHV, Marsden CD (1992) New insights into the cause of Parkinson's disease. Neurology 42: 2241–2250

    Google Scholar 

  • Kagen V, Shvedova A, Serbinova E, Khan SS, Swanson C, Powell R, Packer L (1992) Dihydrolipoic acid — a universal antioxidant both in the membranes and in the aqueous phase. Reduction of peroxyl, ascorbyl and chromanoxyl. Biochem Pharmacol 44: 1637–1649

    Google Scholar 

  • Konig JFR, Klippel RA (1963) The rat brain: a stereotaxic atlas of the forebrain and lower parts of the brainstem. Williams & Wilkins, Baltimore

    Google Scholar 

  • Maitra I, Serbinova E, Tritschler H, Packer L (1995) α-Lipoic acid prevents buthionine sulfoximine-induced cataract formation in newborn rats. Free Rad Biol Med 18: 823–829

    Google Scholar 

  • Mesina JE, Page RH, Hetzel FW, Chopp M (1989) Administration of L-2-oxo-4-thiazolidine carboxylate increase glutathione levels in rat brain. Brain Res 478: 181–183

    Google Scholar 

  • Mizuno Y, Matuda S, Yoshino H, Mori H, Hattori N, Ikebe S-I (1994) An immunohistochemical study on α-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann Neurol 35: 204–210

    Google Scholar 

  • Perry TL, Godin DV, Hansen S (1982) Parkinson's disease: a disorder due to nigral glutathione deficiency. Neurosci Lett 33: 305–310

    Google Scholar 

  • Pileblad E, Magnusson T (1989) Intracerebroventricular administration of L-buthionine sulfoximine. A method for depleting brain glutathione. J Neurochem 53: 1878–1882

    Google Scholar 

  • Pileblad E, Magnusson T, Fornstedt B (1989) Reduction of brain glutathione by L-buthionine sulfoximine potentiates the dopamine-depleting action of 6-OHDA in rat striatum. J Neurochem 52: 978–80

    Google Scholar 

  • Pileblad E, Magnusson T (1992) Increase in rat brain glutathione following intracerebroventricular administration of γ-glutamylcysteine. Biochem Pharmacol 44: 895–903

    Google Scholar 

  • Reed DJ, Babson JR, Beatty PW, Brodie AE, Ellis WW, Potter DW (1980) High performance liquid chromatography anaylsis of nanomole levels of glutathione, glutathione disulphide and related thiols and disulphides. Anal Biochem 106: 55–62

    Google Scholar 

  • Riederer P, Sofic E, Rausch W, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brains. J Neurochem 52: 515–520

    Google Scholar 

  • Rose S, Nomoto M, Jackson E, Gibb W, Jenner P, Marsden CD (1989) Transient depletion of nucleus accumbens dopamine content contribute to initial akinesia induced by MPTP in common marmosets. Neuropharmacology 28: 1211–1216

    Google Scholar 

  • Schapira AHV, Cooper JM, Dexter DT, Jenner P, Clark JB, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54: 820–827

    Google Scholar 

  • Scott BC, Arouma OI, Evans PJ, O'Neill C, Van Der Vliet A, Cross CE, Tritschler H, Halliwell B (1994) Lipoic and dihydrolipoic acids as antioxidants. A critical review. Free Rad Res Commun 20: 119–133

    Google Scholar 

  • Seaton TA, Jenner P, Marsden CD (1995a) Mitochondrial respiratory enzyme function and superoxide dismutase activity following brain glutathione depletion in the rat. J Neurochem (in press)

  • Seaton TA, Jenner P, Marsden CD (1995b) The isomers of thioctic acid alter14C-2-deoxyglucose utilisation in rat basal ganglia. Biochem Pharmacol (in press)

  • Seaton TA, Jenner P, Marsden CD (1995c) Age related changes in14C-2-deoxyglucose incorporation in rat brain produced by the isomers of thioctic acid. Biochem Pharmacol (in press)

  • Seaton TA, Jenner P, Marsden CD (1995d) Alterations in brain14C-2-deoxyglucose incorporation produced by thioctic acid are dependent on basal glucose utilisation. Biochem Pharmacol (in press)

  • Shivakumar BR, Ravindranath V (1992) Oxidative stress induced by administration of the neuroleptic drug haloperidol is attentuated by high doses of haloperidol. Brain Res 595: 256–262

    Google Scholar 

  • Sian J, Dexter DT, Lees AJ, Daniel SE, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (1994a) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36: 348–355

    Google Scholar 

  • Sian J, Dexter DT, Lees AJ, Daniel SE, Jenner P, Marsden CD (1994b) Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol 36: 356–361

    Google Scholar 

  • Sofic E, Lange KW, Jellinger K, Riederer P (1992) Reduced and oxidised glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 142: 128–130

    Google Scholar 

  • Sumathi R, Kalpana Devi V, Varalakshmi P (1994) DL α-Lipoic acid protection against cadmium-induced tissue lipid peroxidation. Med Sci Res 22: 23–25

    Google Scholar 

  • Suzuki YJ, Tsuchya M, Packer L (1991) Thioctic acid and dihydrolipoic acid are novel antioxidants which interact with reactive oxygen species. Free Rad Res Commun 15: 255–263

    Google Scholar 

  • Weiner HJ, Hashim A, Lajtha A, Sershen H (1988) (−)-2-Oxo-4-thiazolidine-carboxylic acid attenuates 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine induced neurotoxicity. Res Commun Abuse 9: 53–60

    Google Scholar 

Download references

Author information

Author notes

  1. P. Jenner

    Present address: Neurodegenerative Disease Research Centre, Pharmacology Group, Biomedical Sciences Division, King's College, London

Authors and Affiliations

  1. Neurodegenerative Disease Research Centre, Pharmacology Group, Biomedical Sciences Division, King's College, London

    T. A. Seaton

  2. University Department of Clinical Neurology, Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK

    C. D. Marsden

Authors
  1. T. A. Seaton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Jenner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. D. Marsden
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seaton, T.A., Jenner, P. & Marsden, C.D. Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain. J. Neural Transmission 103, 315–329 (1996). https://doi.org/10.1007/BF01271243

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01271243

Keywords

Search

Navigation